N Y Y N Y Y Y Y N Y N Y Y Y N Y N N N Y Y Y N N N Y Y N Y Y Y Y N N N Y Y Y Y Y N Y N Y Y Y Y N N Y Y Y Y Y Y N Y N Y Y N Y

Home , N

Sample Serostatus Diagnosis 2006 Criteria for NMO Age at Time from Sent as Final Serology ON Myelitis Imaging Serology Fulfill NMO EDEN No Sampling onset (Y) Gender Ethnicity Pos/Neg Designation R M R M LETM Non-MS Brain AQP4 Pos Criteria 1 46 10 F Caucasian n n Control-RRMS 2 37 2 F Caucasian n n Control-RRMS 3 36 5 F Caucasian n n Control-RRMS 4 46 3 F Suriname n n Control-RRMS 5 43 9 M Caucasian n n Control-RRMS 6 43 14 F Caucasian n n Control-RRMS 7 35 16 M Caucasian n n Control-MS 8 52 2 F Caucasian n n Control-RRMS 9 53 13 M Caucasian positive positive NMO n Y Y n Y Y Y Y 10 34 0 M Caucasian n n NMO n Y n Y Y Y n Y 11 34 0 F Caucasian n n TM n n n Y Y Y n n 12 43 1 F Caucasian positive positive NMO n Y Y n Y Y Y Y 13 49 3 F Caucasian positive positive TM n n n Y Y Y Y n 14 42 11 F Caucasian positive positive NMO Y n Y n Y Y Y Y 15 59 1 F Caucasian positive positive NMO Y n n Y Y Y Y Y 16 47 1 F Caucasian n n NMO Y n Y n Y Y n Y 17 33 6 M Dutch n n ON+TM Y n Y n n Y n n 18 45 15 M Dutch n n Control-RRMS 19 39 1 F Dutch n n NMO Y n Y n Y Y n Y 20 52 11 M Dutch n n TM n n Y n n Y n n 21 69 unknown M Dutch n n Control-PPMS 22 24 0 F Dutch n n Control-RRMS 23 43 4 F Dutch n n NMO Y n n Y Y Y n Y 24 45 0 F Dutch n n NMO n Y n Y Y Y n Y 25 18 7 F Cape Verdean n n Control-RRMS 26 67 1 F Dutch positive positive NMO n Y n Y Y Y Y Y 27 45 2 F Dutch positive n TM n n n Y Y Y n n 28 31 9 F Unknown positive positive NMO n Y Y n Y Y Y Y 29 57 8 F Dutch positive positive NMO n Y n Y Y Y Y Y 30 42 1 M Dutch n n TM n n Y n n (2.5 Y n n 31 44 30 M Dutch n n ON+TM n Y n Y n (but Y n n Mixed (mother 32 21 2 M n n Control-ADEM Marrocan/ father 33 18 1 M Dutch n n ON Y n n n n Y n n 34 35 8 F Cape Verdean positive positive NMO* Y n Y n n Y Y Y 35 29 8 F Thailand positive positive NMO n Y Y n Y Y Y Y 36 52 2 F Dutch positive positive TM n n n Y n (2 Y Y n 37 54 1 F Ghana positive positive NMO n Y Y n Y Y Y Y 38 20 1 F Suriname positive positive ON Y n n n n Y Y n Sample Serostatus Diagnosis 2006 Criteria for NMO Age at Time from Sent as Final Serology ON Myelitis Imaging Serology Fulfill NMO EDEN No Sampling onset (Y) Gender Ethnicity Pos/Neg Designation R M R M LETM Non-MS Brain AQP4 Pos Criteria 39 30 3 F Dutch positive positive NMO Y n n Y Y Y Y Y 40 44 2 F Caucasian n n ON n Y n n n Y n n 41 63 0 F Caucasian positive positive NMO* n Y n Y Y not done Y Y 42 39 0 F Caucasian positive positive TM n n n Y Y Y Y n 43 56 0 F Caucasian positive positive ON n Y n n n Y Y n 44 44 21 F Caucasian positive positive NMO Y n Y n Y Y Y Y 45 0 n n Control-OSMS 46 46 0 F Caucasian positive positive NMO Y n Y n Y Y Y Y 47 34 5 F Caucasian positive n ON+TM* n Y n Y n Y n n 48 70 7 F Caucasian positive positive NMO n Y Y n Y Y Y Y 49 50 2 F Caucasian positive positive NMO Y n n Y Y Y Y Y 50 22 5 F Caucasian positive positive ON Y n n n n Y Y n 51 44 0 F Caucasian positive positive ON Y n n n n Y Y n 52 30 11 F Caucasian positive positive NMO n Y Y n Y Y Y Y 53 51 3 F Caucasian positive positive NMO n Y Y n Y Y Y Y 54 55 17 F Caucasian positive positive TM n n Y n Y Y Y n 55 32 11 F n n Control-RRMS 56 48 2 F n n Control-RRMS 57 26 3 F n n Control-RRMS 58 49 8 F positive positive NMO n Y Y n Y Y Y Y 59 62 7 F positive positive NMO* Y n Y n Y n Y Y 60 55 3 F n n NMO n Y n Y Y Y n Y 61 55 3 F positive positive TM n n Y n Y Y Y n 62 58 14 F positive positive NMO n Y Y n Y Y Y Y 63 65 0 F positive positive TM n n n Y Y Y Y n 64 36 7 F n n NMO Y n Y n Y Y n Y 65 75 6 F positive positive NMO* Y n Y n Y n Y Y 66 53 2 F positive positive NMO Y n n Y Y Y Y Y 67 55 24 F positive positive NMO Y n Y n Y Y Y Y 68 48 5 F positive positive NMO* n Y Y n Y n Y Y 69 38 11 M n n NMO n Y Y n Y Y n Y 70 46 5 M n n NMO n Y Y n Y Y n Y 71 59 10 M n n NMO n Y n Y Y Y n Y 72 26 1 F positive positive TM n n Y n Y Y Y n 73 24 0 F n n Control-RRMS 74 41 9 F n n Control-RRMS 75 48 6 F n n Control-RRMS 76 25 8 F n n Control-RRMS 77 39 13 F n n Control-RRMS Sample Serostatus Diagnosis 2006 Criteria for NMO Age at Time from Sent as Final Serology ON Myelitis Imaging Serology Fulfill NMO EDEN No Sampling onset (Y) Gender Ethnicity Pos/Neg Designation R M R M LETM Non-MS Brain AQP4 Pos Criteria 78 19 7 M n n Control-RRMS 79 42 0 M n n Control-RRMS 80 40 5 F n n Control-RRMS 81 34 1 F n n Control-RRMS 82 33 1 F n n Control-RRMS 83 51 16 F n n Control-RRMS 84 29 1 M n n Control-RRMS 85 0 Caucasian n n Control-RRMS 86 0 Caucasian n n Control-RRMS 87 57 unknown f Caucasian positive positive NMO* n Y Y n Y n Y Y 88 36 13 M Danish n n NMO n Y n Y Y Y n Y 89 21 5 F Danish positive positive NMO Y n Y n Y Y Y Y negative 90 46 7 M Danish n NMO but n Y Y n Y Y n Y 91 30 0 F Danish n n NMO n Y Y n Y Y n Y negative 92 40 24 F Danish n NMO but n Y Y n Y Y n Y 93 52 11 F Danish positive n NMO n Y Y n Y Y n Y 94 36 4 F Danish positive positive NMO Y n n Y Y Y Y Y 95 0 n n Control - headache 96 0 n n Control - headache 97 0 n n Control - headache 98 0 n n Control - headache 99 0 n n Control - headache 100 0 n n Control - headache 101 0 n n Control - headache 102 0 n n Control - headache 103 0 n n Control - headache 104 0 n n Control - headache 105 0 n n Control - headache 106 0 n n Control - headache 107 0 n n Control - headache 108 0 n n Control - headache 109 0 n n Control - headache 110 28 3 F Caucasian n excluded MG 111 31 0 F Asian n n TM n n n Y Y Y n n 112 43 2 F Caucasian n n Control-MS 113 62 9 F Caucasian n n Control-MS 114 25 6 M Afro-Caribbean positive positive NMO n Y Y n Y Y Y Y 115 35 3 F Asian n n NMO n Y n Y Y Y n Y 116 69 20 F Caucasian positive positive TM n n Y n Y Y Y n Sample Serostatus Diagnosis 2006 Criteria for NMO Age at Time from Sent as Final Serology ON Myelitis Imaging Serology Fulfill NMO EDEN No Sampling onset (Y) Gender Ethnicity Pos/Neg Designation R M R M LETM Non-MS Brain AQP4 Pos Criteria 117 55 0 M Caucasian n n Control-OAID/PERM Mixed 118 32 2 F positive n TM n (Caucasian/Asia n n n Y Y Y n 119 55 9 M Caucasian n n Control-OAID/NMT 120 57 1 M Asian positive positive TM n n n Y Y Y Y n 121 0 n n Control - headache 122 0 n n Control - headache 123 0 n n Control - headache 124 0 n n Control - headache 125 0 n n Control - headache 126 0 n n Control - headache 127 0 n n Control - headache 128 0 n n Control - headache 129 0 n n Control - headache 130 0 n n Control - headache 131 0 n n Control - headache 132 0 n n Control - headache 133 0 n n Control - headache 134 0 n n Control - headache 135 45 2 M Caucasian n n TM n n n Y Y Y n n 136 48 3 F Caucasian positive positive NMO Y n n Y Y Y Y Y 137 0 n excluded MG 138 32 17 F Asian positive positive NMO Y n Y n Y Y Y Y 139 42 7 F Caucasian positive positive TM n n Y n Y Y Y n 140 48 10 F Caucasian n excluded MG 141 20 1 F Caucasian positive positive NMO* n Y n Y n Y Y Y 142 34 2 Caucasian n n Control-MS 143 41 13 F Caucasian n n Control - MS 144 64 10 F Caucasian n n Control-MS 145 0 n n Control - headache 146 0 n n Control - headache 147 0 n n Control - headache 148 0 n n Control - headache 149 0 n n Control - headache 150 0 n n Control - headache 151 0 n n Control - headache 152 0 n n Control - headache 153 0 n n Control - headache 154 0 n n Control - headache 155 26 2 Caucasian n n Control-MS Sample Serostatus Diagnosis 2006 Criteria for NMO Age at Time from Sent as Final Serology ON Myelitis Imaging Serology Fulfill NMO EDEN No Sampling onset (Y) Gender Ethnicity Pos/Neg Designation R M R M LETM Non-MS Brain AQP4 Pos Criteria 156 52 2 F Caucasian positive positive ON n Y n n n Y Y n 157 58 0 F Caucasian n n TM n n n Y Y Y n n 158 66 16 M Caucasian n n NMO n Y Y n Y Y n Y 159 36 0 F Caucasian n n TM n n n Y Y Y n n 160 52 2 F Afro-Caribbean positive positive TM n n n Y Y Y Y n 161 51 8 F Caucasian positive positive ON n Y n n n Y Y n 162 31 6 F Caucasian positive n TM n n Y n n Y n n 163 52 4 Asian n excluded MG 164 40 3 F Caucasian positive positive TM n n n Y Y n Y n 165 68 2 F Caucasian positive positive TM n n n Y Y Y Y n 166 62 20 F Caucasian n excluded MG 167 67 1 F Caucasian n n TM n n Y n Y Y n n 168 52 17 M Caucasian positive positive TM n n Y n Y Y Y n 169 47 2 F Caucasian n n Control-MS 170 0 F Caucasian positive positive ON Y n n n n n Y n 171 0 F Caucasian positive positive NMO n Y Y n Y Y Y Y 172 0 F Caucasian n n Control-tumour 173 0 F Asian positive positive NMO* Y n Y n Y n Y Y 174 29 1 F n n Control-CIS 175 35 1 F n n Control-CIS 176 0 F Caucasian n n Control-Susac 177 0 F Caucasian positive positive TM n pa Y n Y not done Y n 178 0 F Caucasian positive positive NMO Y n Y n Y Y Y Y 179 0 M Caucasian n n Control-tumour 180 75 3 F positive positive NMO Y n Y n Y Y Y Y 181 35 0 F n n Control-CIS 182 0 F Caucasian positive positive NMO Y n Y n Y Y Y Y 183 0 F Caucasian positive positive TM n n Y n Y Y Y n 184 0 F Caucasian positive positive NMO n Y n Y Y Y Y Y 185 0 M Caucasian n n NMO Y n Y n Y Y n Y 186 42 2 F positive positive TM n n n Y Y Y Y n 187 66 5 F positive positive TM n n Y n Y Y Y n 188 0 F Caucasian positive positive NMO n Y n Y Y Y Y Y 189 0 F Caucasian n n Control-CTD 190 0 F Caucasian positive n TM n n Y n Y Y n n 191 0 F Caucasian positive positive TM n n Y n Y Y Y n 192 38 0 M n n Control-CIS 193 25 5 F positive positive NMO n Y n Y Y Y Y Y Clinical Details ASSAY ASSAY Brain or Coexisting AID? Disease No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 No.11 No.12 No.13 EDEN No [Y/N] [Y/N] Disorder activity CBA CBA CBA CBA-EI CBA-EI CBA-EI CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO 1 2 3 4 5 6 7 8 9 n Y Sjögren- Rel ++++ ++++ ++++ +++ ++ ++ + ++++ ++++ +++ ++ +++ ++ 10 n n Rel 11 Y n Rel + + 12 n Y SLE Rem +++ ++++ ++++ +++ +++ ++ ++++ ++++ ++++ +++ ++ ++++ +++ 13 n n Rem ++ +++ ++++ ++ ++ ++ ++ +++ +++ ++ + +++ +++ 14 n n Rel ++++ +++ ++++ +++ ++++ +++ ++++ ++++ ++++ +++ +++ +++ +++ 15 n n Rem ++++ ++++ ++++ +++ ++ ++ ++ ++++ +++ +++ ++ +++ +++ 16 n Y Hashimot Rem 17 n n 18 19 n Y Rheumato Rem 20 n n Rem 21 22 23 n n Rem 24 n n Rem 25 26 n n Positive Rem ++ ++++++ ++ + + + +++ ++ + ++ + 27 n n Rem + 28 n n Rel ++++ ++++ ++++ ++ ++ ++ ++ +++ ++++ ++ +++ +++ +++ 29 n Y Myastheni Rem +++++++++ + + + + ++ + + + 30 n n Rem 31 n n Rem 32 33 n n Rel + 34 Y n Rem ++++ ++++ ++++ +++ +++ ++ +++ ++++ ++++ +++ +++ +++ ++++ 35 Y n Rem +++ ++++++++ ++ ++ ++ ++++ +++ +++ ++ + +++ +++ 36 n n Rem ++ ++++++++ ++ ++ ++ ++ +++ +++ ++ ++ +++ +++ 37 n n Rel ++ ++ ++++ +++ ++ ++ ++ ++++ +++ ++ + +++ +++ 38 n n Rem +++++++++ + + + + ++ + Clinical Details ASSAY ASSAY Brain or Coexisting AID? Disease No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 No.11 No.12 No.13 EDEN No [Y/N] [Y/N] Disorder activity CBA CBA CBA CBA-EI CBA-EI CBA-EI CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO 39 n n Rem ++++ ++++ +++ +++ +++ ++ ++++ ++++ ++++ + ++ ++++ ++++ 40 n n Rem + + 41 n n Rem +++ ++++++++ +++ ++ ++ ++ +++ +++ + + ++ ++ 42 n n Rel +++ ++++ ++++ +++ ++ ++ +++ ++++ +++ ++ ++ +++ ++ 43 Y Y SLE, Rel ++++ ++++ ++++ +++ +++ +++ ++ ++++ ++++ ++ +++ ++++ ++ 44 Y n Rem ++++ ++++ +++ ++++ ++++ ++++ ++ ++++ ++++ ++ ++++ +++ ++++ 45 + + 46 n Y Sjögren Rel ++++ ++++ ++++ +++ +++ +++ + ++++ +++ ++ ++ ++ +++ 47 n n Rem 48 n n Rem ++++++++ + + +++ ++ 49 Y n Rem ++ +++++++ ++ ++ ++ ++ +++ +++ + + ++ ++ 50 n n Rem ++++ ++++ ++++ +++ +++ +++ +++ ++++ ++++ +++ +++ +++ +++ 51 n Y thyreoditi Rem ++++ ++++ ++++ +++ +++ ++ ++ ++++ +++ ++ ++ +++ ++ 52 n n Rem ++++ ++++ ++++ +++ +++ +++ ++ ++++ ++++ ++ +++ +++ +++ 53 Y Y SLE Rel ++++ ++++ +++ +++ +++ ++ ++ ++++ ++++ ++ ++ ++ ++ 54 n n Rem ++++ ++++ +++ +++ +++ +++ +++ ++++ ++++ ++ +++ +++ +++ 55 56 57 58 n n Rel ++ +++++++ ++ + ++ ++ ++ +++ + + +++ + 59 Y n Rem ++ +++++++ ++ + ++ ++ ++ +++ + + ++ + 60 Y n Rem 61 n n Rem +++ +++ +++ + + + ++ +++ +++ ++ + +++ ++ 62 n Y SLE, Rem + + + + + + + + Not evaluable + + 63 n Y myastheni Rel +++ ++++ +++ ++ ++ ++ +++ +++ ++++ ++ + +++ ++ 64 Y n Rem 65 n n Rel ++ +++ ++++ ++ ++ ++ ++ ++++++++ ++ + +++ +++ 66 Y SLE, Rem + + + ++++++ + ++ + + + + 67 n n Rem +++ ++++ +++ ++ ++ ++ +++ ++++++++ ++ + ++ ++ 68 Y SLE, Rem ++++ ++++ ++++ +++ ++ +++ ++ ++++ ++++ ++ +++ ++++ +++ 69 n n Rem + 70 n n Rem + 71 Y n Rel + + 72 Y Y Hashimot Rel ++++ ++++ ++++ +++ +++ +++ ++++ ++++ ++++ ++ ++++ ++++ ++ 73 74 75 + 76 + 77 Clinical Details ASSAY ASSAY Brain or Coexisting AID? Disease No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 No.11 No.12 No.13 EDEN No [Y/N] [Y/N] Disorder activity CBA CBA CBA CBA-EI CBA-EI CBA-EI CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO 78 79 80 81 82 83 84 85 86 87 n n n Rem +++ ++++++++ +++ ++ ++ ++ ++++ +++ ++ ++ +++ + 88 Y n Rem 89 n n Rem + + + + + + + + + + 90 Y n Rem 91 Y n Rel 92 Y n Rem 93 n n Rem + + 94 n n ++++ ++++ ++++ ++++ +++ +++ +++ ++++ ++++ ++ ++++ +++ +++ 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 n n Rem 112 + + + 113 + + + 114 n Y SLE Rem +++ +++ ++++ +++ +++ +++ ++++ ++++ ++++ +++ +++ ++++ +++ 115 n n Rem 116 n Y MG Rem ++ +++ +++ ++ ++ ++ + ++ +++ ++ ++ +++ + Clinical Details ASSAY ASSAY Brain or Coexisting AID? Disease No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 No.11 No.12 No.13 EDEN No [Y/N] [Y/N] Disorder activity CBA CBA CBA CBA-EI CBA-EI CBA-EI CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO 117 + 118 n n Rem +++ + 119 + + 120 n Y Sjogrens Rem +++ ++++ ++++ +++ ++ ++ ++ ++++ ++++ ++ +++ ++++ ++ 121 122 123 124 125 126 127 128 129 130 + 131 132 133 134 135 n n Rem 136 n n Rem ++ +++ ++++ ++ ++ ++ +++ ++ ++++ ++ ++ +++ ++ 137 + + 138 Y n Rel +++ +++ +++ ++ ++ ++ +++ +++ +++ ++ +++ ++ 139 n Y Raynaud's Rem ++++++++ +++ +++ ++ ++ ++ ++++ +++ ++ +++ +++ + 140 141 Y n Rem ++ +++++++ ++ ++ ++ + ++ +++ ++ + +++ 142 + + 143 144 + 145 146 147 148 149 150 151 152 153 154 155 + + Clinical Details ASSAY ASSAY Brain or Coexisting AID? Disease No.1 No.2 No.3 No.4 No.5 No.6 No.7 No.8 No.9 No.10 No.11 No.12 No.13 EDEN No [Y/N] [Y/N] Disorder activity CBA CBA CBA CBA-EI CBA-EI CBA-EI CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO CBA-EO 156 n Y hypothyro Rem +++ ++++ ++++ +++ +++ +++ +++ ++++ ++++ ++ +++ +++ +++ 157 n n Rem 158 n n Rem 159 Y n Rel 160 Y n Rem +++ +++ ++++ +++ ++ ++ ++ +++ ++++ +++ ++ ++++ +++ 161 n Y MG with Rem ++ +++ +++ ++ ++ ++ + +++ ++ ++ + +++ + 162 n n Rem + + 163 + 164 Y n Rem + + + + + + 165 n n Rem + + + 166 +++ + 167 n n Rel 168 n n Rem + + + + 169 170 +++ ++ 171 ++++ ++++ ++++ ++++ ++++ +++ ++++ ++++ ++++ +++ ++++ ++++ +++ 172 + + + 173 ++++ ++++ ++++ ++++ ++++ ++++ +++ ++++ ++++ ++++ ++++ +++ ++++ 174 175 176 177 ++ +++ +++ ++ ++ ++ ++ ++ +++ ++ + +++ ++ 178 ++ +++ ++ ++ ++ ++ +++ +++ +++ ++ + +++ +++ 179 180 n Y Myastheni Rem +++ ++++++++ ++ ++ ++ +++ ++++ ++ + + ++ +++ 181 182 +++ ++++++++ ++ ++ ++ ++ +++ +++ ++ ++ ++ +++ 183 +++ +++++++ ++ ++ ++ + ++ +++ ++ + ++ ++ 184 ++ ++++ ++++ ++ ++ ++ +++ ++++ ++++ ++ ++ +++ +++ 185 186 n n Rem ++++ ++++ ++++ +++ +++ +++ +++ ++++ ++++ ++ +++ +++ ++++ 187 Y Y Myastheni Rem ++ ++ ++ ++ ++ + + + ++ + ++ 188 ++++ + ++ + + + ++++ + + +no result, hemolysed 189 190 191 ++++++++++ + + + + + 192 193 n n Rem +++ ++++++++ ++ ++ ++ ++ +++ +++ ++ ++ ++ +++ Positive in ASSAYASSAY No. 14 No. 14 No. 15 No. 15 No. 16 No. 16 No. 17 No. 17 No. 18 No. 19 No. 20 No. 21 No. of EDEN No FACS Raw Data FACS Raw Data FACS Raw Data FACS Raw Data TBA-IHC TBA-IIF TBA-IIF ELISA Assays 1 133 + 368.5 -0.02 ≤0 1 2 370 20.5 0.04 ≤0 0 3 258 + 732 -0.15 ≤0 1 4 -20 -50 -0.1 ≤0 0 5 -29 37.5 -0.01 ≤0 0 6 22 -109.5 -0.09 ≤0 0 7 25 -67.5 -0.23 ≤0 0 8 23 -115 0.06 ≤0 0 9 + + + + 150849 + + + + 7547.5 + + + 15.78 + + + + 1265.9 ++++ ++ ++ ++++ 21 10 41 94 -0.05 ≤0 0 11 26 -117.5 0.19 5.29 1 12 + + + + 179151 + + + 3734 + + 6.9 + + 115.58 ++++ ++ ++++ 20 13 + + + + 147048 + + + 3628.5 + + 4.05 + 42.53 + + + + + + + 20 14 + + + 113211 ++++ 7228 ++++ 16.93 + + + + 588.76 ++++ ++++ ++++ ++++ 21 15 + + + + 132378 + + + + 6929.5 + + + 10.37 + + + 906.01 ++++ ++ ++ ++++ 21 16 28 -14 -0.08 ≤0 0 17 44 -59 -0.04 ≤0 0 18 -24 314.5 0.06 2.08 0 19 220 -51.5 -0.03 + 66.39 1 20 12 -18 -0.02 14.86 0 21 60 2 -0.04 ≤0 0 22 245 -70.5 -0.05 ≤0 0 23 83 -96 -0.25 18.99 0 24 334 + 412.5 -0.06 18.99 1 25 245 -6 -0.02 15.1 0 26 + + + 65973 + + 1219 + 1.11 21.51 + + + 17 27 374 + 915 0.03 14.05 2 28 + + + + 133577 ++++ 7713 ++++ 20.78 + + 159.38 +++ +++ + +++ 21 29 + + + 109823 + + 661.5 + 1.4 + 41.01 + + + + 19 30 96 -62 -0.03 17.04 0 31 29 19 -0.01 20.41 0 32 -72 -25.5 -0.02 13.21 0 33 -25 -19.5 -0.01 ≤0 1 34 + + + 124755 + + + 4112.5 + + + 9.12 + 61.5 +++ +++ + ++++ 21 35 + + + 110352 + + + 3411.5 + + 6.41 + + 470.17 ++++ ++ ++ ++++ 21 36 + + + 112452 + + + 2349.5 + + 4.75 + + 333.7 +++ ++ +++ ++ 21 37 + + 46387 + + 1299.5 + 1.57 10.73 ++++ ++ +++ +++ 20 38 + + 38123 + 494 0.66 28.26 + + + + + + + 16 Positive in ASSAYASSAY No. 14 No. 14 No. 15 No. 15 No. 16 No. 16 No. 17 No. 17 No. 18 No. 19 No. 20 No. 21 No. of EDEN No FACS Raw Data FACS Raw Data FACS Raw Data FACS Raw Data TBA-IHC TBA-IIF TBA-IIF ELISA Assays 39 + + + 122621 + + + 3640 + + + 13.94 + + 109.37 +++ +++ +++ ++++ 21 40 + 2278 -43 0.1 ≤0 3 41 + + + + 133714 + + + 3936.5 + + 5.19 4.03 + + + + + + 19 42 + + + + 150307 + + + 2782.5 + + + 8.24 7.55 +++ + + ++++ 20 43 + + + 112828 ++++ 7083.5 ++++ 20.53 + + + + 854.04 ++++ ++ ++++ 20 44 + + + 102152 ++++ 6751.5 ++++ 20.47 + + + + 1555.1 +++ ++++ ++ + 21 45 178 -78.5 0.05 ≤0 2 46 + + 43278 ++++ 5572 ++++ 19.03 + + + 268.6 ++++ ++ ++++ 20 47 38 + 283 0.11 ≤0 1 48 + + 54747 + + 833.5 + 1.11 ≤0 + + + 15 49 + + + 120074 + + + 2732 + + 4.74 23.59 +++ ++ ++ +++ 20 50 + + + + 146559 ++++ 4458.5 ++++ 20.07 + + + 276.11 ++++ +++ +++ ++++ 21 51 + + + + 155149 ++++ 9750.5 ++++ 16.22 + + 143.85 ++++ +++ + +++ 21 52 + + + + 144059 + + + + 13413.5 + + + + 22.49 + + + 712.26 +++ ++ + ++++ 21 53 + + + + 137911 ++++ 8494.5 ++++ 16.31 + + 260.71 +++ ++ ++++ 20 54 + + + + 150933 ++++ 8977 ++++ 20.23 + + + 413.93 +++ +++ +++ ++++ 21 55 -1718 9688 -0.04 26.9 0 56 -1339 9902 -0.04 ≤0 0 57 -1623 7999 -0.04 15.1 0 58 + + + 110933 + + + 4398.5 + + 4.3 + 39.78 ++++ + +++ +++ 21 59 + + 76439 + + 2490 + 2.48 24.64 + + + + 18 60 169 -164.5 0.02 4.39 + + 1 61 + + + + 147438 + + + 6283 + + 5.34 + 89.42 + + + + + + + 20 62 + 25267 + + 1291.5 -0.06 ≤0 + + 12 63 + + + + 156174 + + + 4925 + + 7.15 + 56.6 + + + + + + + + 21 64 + + 39635 9 0 ≤0 1 65 + + + 128216 + + + 5781.5 + + 5.76 47 + + + + + + + + 20 66 + 10209 + + 1987 -0.03 ≤0 + + + + 16 67 + + + 113153 + + + 5372 + + + 8.1 + 81.93 + + + + + + 19 68 + + + 98505 + + + + 22530.5 + + + + 23.76 + + + 662.63 ++++ ++ +++ 20 69 279 282 -0.03 ≤0 1 70 68 -53.5 0.02 9.44 1 71 60 -209.5 0.02 ≤0 1 72 + + + + 141981 ++++ 9888.5 ++++ 24.05 + + 352.82 ++++ +++ +++ +++ 21 73 73 91 0.02 ≤0 0 74 43 -141.5 0.03 ≤0 0 75 83 -129 0.03 ≤0 + 2 76 + 628 59 0.01 5.37 2 77 111 -98.5 0.03 ≤0 0 Positive in ASSAYASSAY No. 14 No. 14 No. 15 No. 15 No. 16 No. 16 No. 17 No. 17 No. 18 No. 19 No. 20 No. 21 No. of EDEN No FACS Raw Data FACS Raw Data FACS Raw Data FACS Raw Data TBA-IHC TBA-IIF TBA-IIF ELISA Assays 78 52 -123 -0.02 ≤0 0 79 58 -112 0 11.72 0 80 69 -79.5 0 ≤0 0 81 -196 59 0.09 + 84.45 1 82 15 -66.5 0.01 ≤0 0 83 250 -121 0.02 4.73 0 84 17 -226.5 0.01 ≤0 0 85 -1893 10874.5 0.02 21.17 0 86 -1715 10153 0.02 11.03 0 87 + + + 117769 + + + 7519.5 + + 5.16 + + 508.34 + + + + + + + 21 88 23 -43 -0.01 11.66 0 89 + + 18206 + 395.5 0.31 4.77 + + + 11 90 -30 -99.5 0.02 ≤0 0 91 -7 + + 928.5 -0.32 ≤0 1 92 40 203.5 -0.2 ≤0 0 93 -142 42.5 -0.34 + 69.71 + 3 94 + + + 106723 + + + + 15630.5 + + + + 18.23 + + + + 678.65 ++++ +++ ++ ++++ 21 95 62 -28 -0.04 ≤0 0 96 -32 -66.5 -0.03 4.48 0 97 63 -49.5 -0.03 ≤0 0 98 + 1219 25.5 -0.19 ≤0 1 99 -49 -68 -0.2 + 60.16 1 100 -73 7.5 -0.09 1.23 0 101 8 -29.5 -0.03 21.33 0 102 93 -12 -0.05 25.03 0 103 59 10 -0.07 + 65.91 1 104 194 -7.5 -0.25 ≤0 0 105 31 -62.5 0.01 17.04 0 106 26 -24.5 0 3.69 + + 1 107 26 -101 0.01 4.75 0 108 20 -13.5 -0.04 ≤0 + + 1 109 -114 134.5 -0.07 13.54 0 110 42 -28 -0.02 35.09 0 111 -203 9.5 -0.06 ≤0 0 112 103 -49.5 0.01 13.85 1 113 51 -44.5 0.01 ≤0 1 114 + + + 107303 + + + + 25110 + + + 15.23 + + + + 1159.9 +++ ++ ++ +++ 21 115 35 13 -0.02 43.58 0 116 + + + 74979 + + 1713.5 0.65 6.14 + + + + + + 19 Positive in ASSAYASSAY No. 14 No. 14 No. 15 No. 15 No. 16 No. 16 No. 17 No. 17 No. 18 No. 19 No. 20 No. 21 No. of EDEN No FACS Raw Data FACS Raw Data FACS Raw Data FACS Raw Data TBA-IHC TBA-IIF TBA-IIF ELISA Assays 117 32 -72 0.04 6.72 1 118 -15 -24.5 -0.02 4.6 + + 4 119 + + 15481 -177 0.02 ≤0 2 120 + + + 107110 + + + + 11260 + + 7.48 + 110.4 +++ ++ +++ ++ 21 121 33 -27.5 -0.02 26.88 0 122 52 -20 0 8.88 0 123 36 -46.5 -0.01 18.46 0 124 49 -51.5 0.02 10.15 0 125 -68 -27 -0.04 ≤0 0 126 -88 430 -0.09 16.56 0 127 -41 163.5 -0.05 20.16 0 128 -3 22.5 0.03 42.04 0 129 23 43.5 -0.17 + 140.27 1 130 25 + 530 -0.17 72.83 2 131 -18 -30.5 -0.02 69.71 0 132 65 -12.5 -0.06 43.58 0 133 -50 14.5 -0.04 ≤0 0 134 13 3 -0.01 0.88 + 1 135 -20 -131.5 0.02 3.98 0 136 + + 26420 + + + + 10850 + + 4.78 + 172.53 + + + + + + + + 20 137 111 -17.5 -0.02 37.72 1 138 + + + 127325 ++++ 9753 +++ 8.82 + + 219.52 + + + + + + 19 139 + + + 101996 + + + + 13060 + + + 13.12 + + 365.79 ++++ ++ + ++++ 21 140 111 32 -0.08 8.91 0 141 + + + 80627 + + 2314 + 1.05 + 45.35 + + + + + + 19 142 89 -65.5 0.09 + + 149.99 + 4 143 36 11 0.04 17.01 0 144 15 -65.5 0.04 15.55 1 145 -420 9.5 0.02 ≤0 0 146 29 14 0.05 27.21 0 147 19 -62.5 -0.12 + + 278.61 1 148 -5 18 0.06 65.36 0 149 42 158 0.09 44.34 0 150 27 -71 0.04 + 56.35 1 151 225 29.5 0.05 60.8 0 152 -298 103 0.01 + + 180.62 1 153 224 96.5 0.07 71.28 + + + 1 154 77 7.5 0.04 9.21 0 155 87 -140.5 0.05 + 172.64 2 Positive in ASSAYASSAY No. 14 No. 14 No. 15 No. 15 No. 16 No. 16 No. 17 No. 17 No. 18 No. 19 No. 20 No. 21 No. of EDEN No FACS Raw Data FACS Raw Data FACS Raw Data FACS Raw Data TBA-IHC TBA-IIF TBA-IIF ELISA Assays 156 + + + 136266 + + + + 53356.5 + + + 13.09 + + 409.85 +++ +++ +++ 20 157 20 + 299.5 0.06 ≤0 1 158 129 -54 -0.97 ≤0 0 159 19 -86.5 0.04 + 120.2 1 160 + + + 121441 + + + + 29106.5 + + + 11.84 + + 172.31 +++ ++ ++++ 20 161 + + + 79950 + + + 7682 + 2.87 + 133.9 + + + + 20 162 74 + 271.5 -0.08 ≤0 3 163 662 + 586 -0.04 11.97 + 3 164 + + 15742 + 573.5 0.08 ≤0 + + 8 165 + 9435 -28.5 0.06 5.29 + 5 166 + 7145 + 573 0.06 ≤0 + + 6 167 -40 -45.5 -0.02 ≤0 0 168 + + 10022 + 397 0.14 ≤0 + 6 169 1 -88 -0.02 ≤0 0 170 + + 9929 96.5 0.04 ≤0 + 6 171 + + + 118563 + + + + 40531.5 + + + + 40.43 + + + 1160.4 ++++ +++ ++++ 20 172 66 -171 0.01 ≤0 1 173 + + + 87667 + + + + 48391 + + + + 39.18 + + + + 1269.9 ++++ +++ +++ 20 174 285 -132.5 0 ≤0 0 175 143 -86 0 ≤0 0 176 114 21.5 -0.01 2.31 0 177 + + 60659 + + + 8955 + + 6.82 + 75.06 + + 19 178 + + 53244 + + + 3125 + 1.24 17.66 + + + + 19 179 -79 -88 0 ≤0 0 180 + + + 86461 + + + + 31420.5 + + + 13.95 + + + 932.73 + + + + 19 181 385 -136.5 0.06 ≤0 0 182 + + + 122437 + + + + 13072.5 + + 4.68 + + 418.93 ++++ ++ + +++ 21 183 + + + 75688 + + + + 13300.5 + + 4.15 + + 241.1 ++++ ++ ++++ + 21 184 + + 48095 + + + + 15793 + + 6.45 + + + 533.69 ++++ + ++++ 20 185 + + 31414 -178.5 0.05 ≤0 1 186 + + + 118640 + + + + 33070 + + + + 16.01 + + + + 1195.1 ++++ +++ +++ ++++ 21 187 + + 12932 + 818.5 0.4 18.62 + + + 16 188 + + 59940 + + + 10915.5 + + 4.19 + + 174.13 + + + + 18 189 497 210 -0.31 ≤0 + 1 190 + 2043 104 0.31 ≤0 + 2 191 + + 31248 + + 2177 0.72 28.82 + + + 14 192 + 665 -51.5 0.06 ≤0 1 193 + + + 91785 + + + + 19895.5 + + + 8.93 + + + 733.9 +++ +++ + +++ 21